Frailty, Sarcopenia, and Functional Decline After CAR-T Therapy: The Case for Structured Rehabilitation.

Area of Science:

• Oncology
• Immunotherapy
• Cardiovascular Health

Background:

• Chimeric antigen receptor T-cell (CAR-T) therapy has transformed hematologic malignancy treatment.
• Focus is shifting from acute toxicities to long-term survivorship and quality of life.

Purpose of the Study:

• To highlight underrecognized long-term complications in CAR-T therapy survivors.
• To emphasize the importance of functional outcomes and rehabilitation in CAR-T survivorship care.

Main Methods:

• Review of emerging evidence on CAR-T therapy survivorship.
• Analysis of factors contributing to functional decline post-CAR-T therapy.

Main Results:

• Emerging evidence indicates frailty, sarcopenia, and functional decline are common in CAR-T survivors.
• These impairments may stem from inflammation, prior treatments, and inactivity.
• Potential cardiovascular implications include reduced fitness and increased morbidity.

Conclusions:

• CAR-T survivorship requires a framework addressing functional outcomes and quality of life.
• Structured rehabilitation programs are crucial but currently underintegrated into survivorship care.
• Addressing frailty and functional decline is essential for long-term CAR-T patient well-being.